MYD88 and cancer: On the other hand, Alvero et al. reported that CD44+MyD88+ cancer stem cells possessed a mainly glycolytic phenotype and proposed that maintenance therapy with glycolytic inhibitors could be beneficial to improve patient’s survival48.